美股市場個股詳情

FOLD 愛美醫療

添加自選

9.330
+0.290+3.21%

收盤價 05/14 16:00 (美東)

9.330
0.0000.00%

盤前 08:16 (美東)

27.64億總市值-19040市盈率TTM

愛美醫療股票討論區

登錄發表評論

Moomoo AI

02/07 20:42

Despite Amicus Therapeutics' recent share price uptick and steady revenue growth, the market's high expectations are reflected in the share price fall over the past three years. The company's 3.2% total shareholder return over the last twelve months falls short of the market return.

Strong Week for Amicus Therapeutics (NASDAQ:FOLD) Shareholders Doesn't Alleviate Pain of Three-year Loss

Moomoo AI

01/03 19:28

Investors might overlook Amicus Therapeutics' below industry-level growth forecast, risking future disappointment if the P/S ratio falls in line with the growth outlook. Moderate P/S ratio poses a risk as weaker revenue outlook might lead to share price drop.

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Shares Climb 28% But Its Business Is Yet to Catch Up

Mini0n

2023/09/29 00:13

$愛美醫療(FOLD.US)$ Good thing this didn't have any bad news, jesus

73015995

2023/09/28 23:06

$愛美醫療(FOLD.US)$ FDA approval 🚀🙏🏻

Mini0n

2023/09/28 20:50

$愛美醫療(FOLD.US)$ News halt...... watching

Mantou

2023/08/16 11:56

Amicus announces U.K. approval and launch of Pompe disease therapy

$愛美醫療(FOLD.US)$

Alvinnnnnnngenius

2023/08/15 19:37

$愛美醫療(FOLD.US)$ Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis.
GALACTIC-1 trial did not meet its primary endpoint.
Galecto to discontinue the development of GB0139.

WallStreetYoda

2022/10/14 03:09

$愛美醫療(FOLD.US)$ Following the sale, the chief executive officer now owns 689,618 shares of the company's stock, valued at approximately $7,261,677.54. he just needed the money for somthing if it was bad news we dont know yet then he would have sold way more